Results 71 to 80 of about 1,324,681 (290)

POLA TERAPI ANTIHIPERTENSI BERDASARKAN COMPELLING INDICATION PADA PASIEN RAWAT JALAN UNIT PELAYANAN JANTUNG RSUP DR. KARIADI SEMARANG [PDF]

open access: yes, 2015
Background Drug of choice on antihypertensive therapy is influenced by various factors, one of them is whether there is a compelling indication or not in hypertensive patients.
Ardhianto, Pipin   +2 more
core   +1 more source

How developing world concerns need to be part of drug development plans: A case study of four emerging antiretrovirals [PDF]

open access: yes, 2008
Clinical trials are usually designed to meet registration requirements in developed countries, and do not always address key concerns for use in developing countries.
Alexandra Calmy   +22 more
core   +2 more sources

Clinical applications of next‐generation sequencing‐based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progression

open access: yesMolecular Oncology, EarlyView.
Circulating tumor DNA (ctDNA) offers a possibility for different applications in early and late stage breast cancer management. In early breast cancer tumor informed approaches are increasingly used for detecting molecular residual disease (MRD) and early recurrence. In advanced stage, ctDNA provides a possibility for monitoring disease progression and
Eva Valentina Klocker   +14 more
wiley   +1 more source

Providing antiretroviral care in conflict settings. [PDF]

open access: yes, 2009
There has been an historic expectation that delivering combination antiretroviral therapy (cART) to populations affected by violent conflict is untenable due to population movement and separation of drug supplies. There is now emerging evidence that cART
Eyawo, Oghenowede   +3 more
core   +2 more sources

Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients

open access: yesMolecular Oncology, EarlyView.
Small cell lung cancer (SCLC) is an aggressive form of lung cancer that spreads rapidly to secondary sites such as the brain and liver. Cancer cells circulating in the blood, “circulating tumor cells” (CTCs), have demonstrated prognostic value in SCLC, and evaluating biomarkers on CTCs could guide treatment decisions such as for PARP inhibitors ...
Prajwol Shrestha   +6 more
wiley   +1 more source

A Systematic Review: Comparison of triple drug therapy versus double drug therapy for Lymphatic Filariasis

open access: yesMedical and Health Science Journal, 2021
Background: Lymphatic filariasis is a parasitic infection caused by nematodes such as filaria Wuchereria bancrofti, Brugia malayi, and Brugia timori.
I Gusti Agung Ari Kusuma Yana
doaj   +1 more source

Dynamic ploidy changes drive fluconazole resistance in human cryptococcal meningitis. [PDF]

open access: yes, 2018
BACKGROUND: Cryptococcal meningitis (CM) causes an estimated 180,000 deaths annually, predominantly in sub-Saharan Africa, where most patients receive fluconazole (FLC) monotherapy. While relapse after FLC monotherapy with resistant strains is frequently
Berman, J   +13 more
core   +4 more sources

Cell‐free and extracellular vesicle microRNAs with clinical utility for solid tumors

open access: yesMolecular Oncology, EarlyView.
Cell‐free microRNAs (cfmiRs) are small‐RNA circulating molecules detectable in almost all body biofluids. Innovative technologies have improved the application of cfmiRs to oncology, with a focus on clinical needs for different solid tumors, but with emphasis on diagnosis, prognosis, cancer recurrence, as well as treatment monitoring.
Yoshinori Hayashi   +6 more
wiley   +1 more source

Enhanced cancer therapy with cold-controlled drug release and photothermal warming enabled by one nanoplatform [PDF]

open access: yes, 2018
Stimuli-responsive nanoparticles hold great promise for drug delivery to improve the safety and efficacy of cancer therapy. One of the most investigated stimuli-responsive strategies is to induce drug release by heating with laser, ultrasound, or ...
Agarwal, Pranay   +7 more
core   +1 more source

Efficacy and safety of anticancer drug combinations: a meta-analysis of randomized trials with a focus on immunotherapeutics and gene-targeted compounds. [PDF]

open access: yes, 2020
Hundreds of trials are being conducted to evaluate combination of newer targeted drugs as well as immunotherapy. Our aim was to compare efficacy and safety of combination versus single non-cytotoxic anticancer agents. We searched PubMed (01/01/2001 to 03/
Barkauskas, Donald A   +4 more
core   +1 more source

Home - About - Disclaimer - Privacy